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INTRODUCTION 
The occurrence of bloodstream infections (BSI) has 
increased among hospitalized patients over the last 
decade [l]. In recent years Gram-positive bacteria have 
emerged as important pathogens, both in the com- 
munity and hospital. To compound these problems, 
antimicrobial resistance long considered the domain of 
Gram-negative bacteria, is being increasingly exhibited 
by Gram-positive strains [2]. 
Three etiologic factors have made major contribu- 
tions to the increase in the relative frequency of Gram- 
positive BSI among all nosocomial infections. These 
include shifts in patient demographics, the increased 
use of intravascular and other prosthetic devices, and 
the increased use of broad-spectrum antibiotics, such as 
the cephalosporins. To a lesser extent, a change in 
defining criteria for coagulase-negative staphylococcal 
bloodstream infection may also have contributed to this 
trend. However, the increase in the number of hospital- 
ized patients at risk for such infections may be the single 
most important factor. Of the 35 million patients 
admitted to US hospitals each year, at least 2.5 million 
will develop a nosocomial infection, of which 250 000 
will be bacteremic episodes. The attack rate for noso- 
comial BSI range from 1.3 to 14.5 per 1000 hospital 
admissions, varying with the type of population 
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studied, size of hospital, length of hospital stay and the 
ward location of the patient within a hospital [3]. 
Since the early 1980s the contribution of BSI to 
the total incidence of nosocomial infections has 
increased at the same time as the relative proportion of 
BSI caused by Gram-positive organisms has increased 
[1,4-111. Table 1 shows the changing patterns of 
bacterenlic isolates as reported to Microbe Base (Glaxo- 
Wellcome) National Computerized Data Base com- 
prising in excess of 1.7 million patient records 
downloaded from the laboratory computer system of 
61 participating UK laboratories over ten years [12]. 
The ratio of Gram-positive bacterial isolates to Gram- 
negative strains has increased from 1.5:l to 4.3:l 
between 1986 and 1998. 
The increase in the proportion of BSI caused by 
Gram-positive bacteria has been directly related to 
hospital size and to the treatment environment, which 
is typically more complex in teaching hospitals than 
in non-teaching hospitals. Table 2 shows the most 
common species isolated from blood cultures in the 
United Bristol Hospitals Trust (UBHT), a tertiary 
referral complex of hospitals. As can be seen, Gram- 
positive isolates predominate in immunocompromised 
patients when compared with the overall hospital 
population and in the care of the elderly, where Gram- 
negatives predominate. 
Banerjee et al. [5] reported on a ten-year period, 
between 1980 and 1989 when >25000 primary 
bloodstream infections were identified by 124 NNIS 
hospitals performing hospital-wide surveillance. Sig- 
nificant increases occurred (p<0.0001) within each 
hospital stratum-small non-teaching (<200 beds), 
small teaching (<500 beds), large non-teaching (>200 
beds), large teaching (> 500 beds)-in overall BSI rates 
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Table 1 Distribution % of bacteremia isolates as reported 
to Microbe Base between 1986 and 1998 (total no. of 
bacteremia isolates = 396 433) 
1986 1990 1994 1998 
Coag.-neg. staph. 30.2 39 49.2 48.8 
E. coli 19.3 14.8 12.8 8.2 
Staph. aureus 15.2 10.7 9.7 12.5 
S.  pneumoniae 3.3 4.8 3.2 3.5 
Enterococci 2.9 2.2 2.7 6.1 
Klebsiella spp 2.9 2.4 2.9 3.0 
Table 2 Blood cultures (UBHT) total patient episodes 
% occurrence 
Whole lmmuno- Care of 
hospital compromised Eldery 
(n=560) (n=110) (n=150) 
E. coli 21 11 
Coag. neg. staph. 16 50 
S. pneumoniae 9 0 
Staph. aureus I 2 
Enterococci 7 5 
MRSA 6 2 








and the BSI rate due to coagulase-negative staphy- 
lococci (increases 161-754%); StaphyEococctrs atrietrx 
(increases 122-283%) and enterococci (increases 
120-197%). By contrast, the BSI rate due to Gram- 
negative bacilli remained constant. 
Pittet et al. [13] studied the effect of nosocomial 
BSIs in critically ill patients and estimated the 
attributable mortality rate to be 35%. They calculated 
that the extra stay in hospital was 24 days and the extra 
stay in intensive care units was eight days when 
compared with matched controls (n=41). The extra 
cost was calculated to be on average 40 000 US dollars 
per survivor. The Of ice  of Technology Assessment of 
the US Congress in their report [14] calculated the 
costs of bacteremia caused by some antibiotic-resistant 
strains. The cost of MRSA bacteremia was calculated 
at  10 million US dollars; VRE bacteremia 2.6 million 
dollars; and methicillin-resistant coagulase-negative 
staphylococcal bacteremia to be 56 million dollars. 
Neutropenic patients are a group of patients at 
particular risk of BSI from Gram-positive bacteria [15]. 
In the eight-year period between EORTC trials I 
(1973-1976) and XI (1993-1994) the percentage of 
Gram-negative bacteremia decreased from 71% to 3 1%; 
whilst that of Gram-positive bacteremia increased from 
29% to 69%. Coagulase-negative staphylococci have 
been recognized as the leading pathogen causing 
nosocomial bacteremia in general, accounting for about 
one-quarter of all bloodstream infection [3] as well as 
in the neutropenic host. Viridans streptococci, initially 
considered to be pathogenic only in the setting of 
infective endocarditis, have now become prominent as 
one of the leading organisms to cause bacteremia in 
neutropenic patients. Enterococci are becoming an 
increasingly common cause of hospital-acquired bac- 
teremia, being cited as the third most common 
pathogen in some series [16]. In addition to increasing 
its numbers there has been a change in the species- 
causing infection, with E. faerium increasingly taking 
over from E. faecalis as the predominant cause of serious 
infection [17]. Hand in hand with the increasing 
frequency has been the development of antibiotic 
resistance, especially to the glycopeptides. Resistance 
occurs when strains of enterococci produce structurally 
related ligases (Van A and Van B) which synthesize 
altered precursors that bind the glycopeptides with a 
reduced affinity, altering cell wall production in the 
presence of the antibiotic [18]. Bacteremia is often 
associated with fatal outcome, although this may reflect 
the relationship between bacteremia and severe under- 
lying disease, rather than any particular virulence of the 
organism. 
The European Prevalence of Infection in Intensive 
Care (EPIC) Study was conceived as a point prevalence 
study of infection [19]. O f  the 10038 patients, a total 
of 4 501 had one or more infections on the EPIC Study 
day: 13.7% (1,376 cases) were community acquired, 
9.7% (975 cases) were hospital acquired, 20.6% (2064 
cases) were ICU acquired and in a small minority of 
cases no information was given on where the infection 
was acquired. Infections acquired in ICUs therefore 
constituted almost half (45.9%) of all cases of infection 
for which a source of acquisition was indicated. In most 
of these cases, a single infection was present: only 25.6% 
of ICU-infected patients had two or more infection. 
Bacteremia was reported in 12% of ICU-acquired 
infections [20]. The results of the EPIC study are in line 
with previous reports that have documented the 
emergence of coagulase-negative staphylococci as 
increasingly important nosocomial ICU pathogens, 
especially in bloodstream infections [7]. These bacteria 
were the most commonly isolated organisms in 
laboratory-confirmed ICU-acquired bloodstream infec- 
tions. Coagulase-negative staphylococci were generally 
reported to be highly resistant to antimicrobial agents, 
although they generally remained sensitive to vanco- 
mycin and (to a lesser degree) teicoplanin. The increase 
in coagulase-negative staphylococcal bloodstream infec- 
tions has been attributed to the increasing use of 
intravascular catheters, with subsequent colonization of 
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the catheters and the development of invasive disease 
171. The findings of the EPIC Study are in accordance 
with this: 67% of patients who developed bloodstream 
infections in an 1CU had intravenous catheters, 61% 
had arterial catheters, and 88% had central venous 
pressure lines [20]. 
As mentioned previously, the increase in incidence 
of Gram-positive bacteria as etiological agents of BSI 
has been mirrored by problems associated with an 
increase in antimicrobial resistance [21]. Heterogeneous 
resistance to glycopeptides in strains of MRSA have 
been reported [22,23]. Viridans streptococci which 
were previously universally susceptible to penicillin 
have been increasingly penicillin-resistant over the past 
decade [24]. Strains of coagulase-negative staphylococci, 
which are relatively resistant to glycopeptides, have been 
described in several clinical settings [25]. Since the first 
description of vancomycin-resistant enterococci by 
Uttley et al. [26] VRE have become well established 
nosocomial pathogens worldwide. There is also the 
problem for the explosive development of macrolide 
resistance in streptococci. The prevalence of macrolide 
resistance reached 60-70% in Japan and 60%) in Spain 
[21]. A recent study in Finland has shown a direct 
correlation between the amount of macrolide usage and 
the emergence of erythromycin-resistant strains of 
S. pyogener in Finland [27,28]. Perhaps of even greater 
concern is the potential for the emergence of macrolide 
resistance in penicillin-resistant strains of Streptococcus 
pneumoniae. Although the overall prevalence of macro- 
lide resistance in S.pneumoniae in Europe and the 
United States is in the relatively low range of 5% to 
10% [29], the prevalence of macrolide resistance in 
penicillin-resistant pneumococci is considerably higher, 
nearing 20% or more in some studies [29]. These 
developments warrant careful observation over the 
coming years, representing the increasing problems 
caused by antibiotic-resistant Gram-positive cocci. 
COAGULASE-NEGATIVE STAPHYLOCOCCI 
Coagulase-negative staphylococci are the most common 
cause of foreign body device infection and nosocomial 
bactereniia. Because of the expanding use of intra- 
vascular catheters and prosthetic devices, this problem 
continues to grow at an alarming rate [3,5,30-331. 
There are increasing numbers of imniunocompro- 
mised and critically ill patients dependent in their care 
on vascular catheters, such as neutropenic patients with 
cancer and long-term central venous catheters, or 
critically ill neonates with umbilical catheters. These 
patients are all prone to contract coagulase-negative 
staphylococcal bacteremia either from the skin via the 
IV catheters or gastrointestinal tract [34]. Such organ- 
isms have been reported as the most common cause of 
bacteremia in leukaemic patients and up to 75% of all 
nosocomial bacteremia in a neonatal intensive care unit 
[35]. Risk factors specific to coagulase-negative staphy- 
lococci as causes of nosocomial bacteremia include: 
presence of intravascular catheters 
length of hospital stay 
use of intravenous lipids in total parenteral nutrition 





Fidalgo et al. [36] found an associated overall death 
rate of 36.9% in cases of coagulase negative staphy- 
lococcal BSI. Underlying disease, hemodynaniic status, 
neutropenia, immunosuppressive therapy and incorrect 
antimicrobial therapy were all statistically significant 
parameters in relation to mortality. 
Although recognized as true pathogens, the most 
frequent encounter by clinicians is as a culture 
contaminant. In a large Spanish study [36],  the results 
of 31 000 blood cultures taken between 1982 and 1987 
in a large tertiary referral hospital were reviewed. O f  
the 5 198 positive cultures 48% yielded CNS of which 
87% were considered contaminants. At present we lack 
a standard method for differentiating between CNS 
as true pathogens and when it occurs as a culture 
contaminant. It  has been suggested that molecular 
typing methods may help differentiate between the two 
groups, but they are not generally available and results 
are not available in the early treatment period [37]. 
In contrast to their infrequent role as a cause of native 
valve endocarditis (1-3(%), CNS are the most common 
bacteria infecting prosthetic cardiac valves, (30-50%), 
occurring within the first 12 months following 
surgery [38]. 
Two properties may explain the association of 
bacteremia with the use of indwelling intravascular 
catheters: the ability to adhere to foreign bodies and 
artificial surfaces due to adhesins and the production of 
extracellular glycocalyx (slime) [39]. A significant 
proportion of coagulase-negative staphylococci bac- 
terenlia could be avoided by the prevention of device- 
associated nosocomial infection [39,40-431, using 
catheters impregnated with metals, disinfectants or 
antibiotics. 
At the same time as an increase in prevalence has 
occurred, an increase in antibiotic resistance has also 
happened [2,21]. Coagulase-negative staphylococci 
from nosocomial infections, especially S. epidermidir and 
S. haemolyticus, are usually resistant to multiple anti- 
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biotics, with more that 80% resistant to methicillin [44]. 
In addition to p-lactam agents, many coagulase-negative 
staphylococcal strains are resistant to macrolides, amino- 
glycosides and lincosamides. Strains of S. kaemolyticus 
are especially resistant to teicoplanin and also, though 
less frequently, to vancomycin [25,45]. However, at 
the moment the glycopeptide antibiotics such as 
vancomycin and teicoplanin, together with rifampicin, 
are the mainstay of the treatment of coagulase-negative 
staphylococcal bacteremia. The efficacy of fluoro- 
quinolones in the treatment of such infections has yet 
to be accurately delineated, but resistance in colonizing 
strains of coagulase-negative staphylococci rapidly 
emerges in patients receiving ciprofloxacin [46]. 
STAPHYLOCOCCUS AUREUS 
In most cases, S. aureus bacteremia is the consequence 
of invasion from a local infection. Such infected foci 
can be categorized as extravascular foci, such as cellu- 
litis, surgical wound infection, osteomyelitis, pneu- 
monia; intravascular foci, such as intravascular catheters; 
and presumed intravascular foci such as intravenous 
drug abusers [47]. However, in about 30% of 
bacteremic patients, no focus of infection can be found. 
The diagnosis of acute endocarditis, caused by S. aureus, 
carries an ominous prognosis with a mortahty of some 
60% [47]. Patients colonized by MRSA are at risk of 
developing bacteremia which can lead to significant 
morbidity and mortality [48]. It has been estimated that 
bacteremia occurs in 1-3% of nosocomial MRSA 
bacteriuria [49]. Risk factors for MRSA bacteremia 
include: [4,48,50-521 
MRSA colonization 
9 severe underlying disease 
poor clinical prognosis 
immobilization and age 
previous broad-spectrum antibiotic use 
previous surgery 
selective gut decontamination 
prolonged length of hospital stay 
Among cases of S. aureus bacteremia reported in 
England and Wales [53,54] the proportion due to 
MRSA has increased significantly from 1.6% in 1989 
to 13.2% by 1995, 21.1% in 1996 and 31.7% in 1997. 
At the same time, there were significant increases in 
resistance to erythromycin (7.5% to 18.7%); gentamicin 
(2.5% to 5.3%) and ciprofloxacin (2.9% to 23.1%). 
Rates of multi-resistance to these unrelated drugs 
were much higher amongst MRSA isolates, than 
methicillin-sensitive strains. In a report from Brazil, 
Conterno et al. [55] found the prevalence of MRSA 
bacteremia varied from 5% to 50% depending on the 
characterization and size of the hospital. In the United 
States approximately 25% of staphylococcal bacteremia 
are caused by MRSA, and significantly higher rates 
have been reported from hospitals where MRSA is 
endemic [ l l ] .  By comparison, Denmark shows an 
incidence of only 0.1% MRSA in staphylococcal 
bacteremia [56]. 
Uncertainties remain about the contribution of 
methicillin resistance to morbidity and mortality associ- 
ated with bacteremia caused by S. aureus. Romero- 
Vivas et al. [57] showed that nosocomial bacteremia 
due to MRSA was associated with a threefold higher 
mortality than MSSA BSI after adjustment for several 
risk factors. However, Harbarth et al. [40] found that 
MRSA had no significant impact on patient outcome 
as measured by in-hospital mortality after adjustment 
was made for major confounders. French et al., from 
Hong Kong [58], showed that MRSA bacteremia had 
a poor prognosis, especially when not treated with 
suitable antibiotics. They showed that five (14.8%) of 
35 patients with MRSA bacteremia treated with vanco- 
mycin died. Of 47 patients with MRSA bacteremia 
treated with antibiotics other than vancomycin, 28 
(60%) died. Vancomycin thus remains the first line drug 
of choice for MRSA bacteremia, the findings of 
Hiramatsu and others notwithstanding [22,23]. 
Teicoplanin is the alternative glycopeptide but must 
be given in high doses, because of the high failure 
rate associated with a single loading dose of 400 mg, 
followed by 200 mg daily [59], while 6 mg/kg body 
weight, or 400 mg daily, remains effective. A minimum 
course of four weeks is mandatory. 
There is little convincing evidence to suggest that 
MRSA is less pathogenic, especially in the vulnerable 
patient. The outcome of MRSA infections is at least 
similar to that of MSSA infections, when mortality is 
corrected for underlying disease. In a comparison of 
ventilator-associated pneumonia caused by MRSA and 
MSSA there was a higher incidence of bacteremia 
and septic shock in patients with MRSA and, when 
allowing for other variables, higher mortality [60]. In a 
prospective study of 84 cases of MRSA bacteremia 
compared with 100 cases of MSSA bacteremia, statis- 
tical analysis showed that methicillin-resistance was 
independently associated with death due to S. aureus 
bacteremia, and the mortality was three times higher in 
patients in the MRSA group [57]. They also found that 
patients acquiring MRSA in intensive care had a longer 
duration of stay, higher overall mortality and required 
more antibiotics. Burns units are also places that 
provide a fertile environment for MRSA where bac- 
teremia may be a serious complication following 
extensive colonization [61]. 
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Nosocomial S. aureus bacteremia, particularly 
MRSA, is a major source of preventable morbidity and 
mortality, which can only be addressed by an improved 
infection control programme for MRSA, the proper 
use of antibiotics and the attention to central line 
catheter use [62]. 
ENTEROCOCCI 
Enterococci are opportunistic pathogens of low 
virulence whose ability to cause bacteremic disease is 
closely linked to the compromised host's absence of 
local or systemic defences. Vancomycin-resistant enter- 
ococci were first reported from London in 1986 [26], 
since when they have become a worldwide problem 
1631. Vancomycin resistance increased from 0.3% in 
1988 to 14.4% by 1996 in United States bacteremia 
enterococcal isolates 117,641. Enterococci are now 
consistently in the top three of US nosocomial blood- 
stream infections. Enterococcus faecium is increasing as a 
percentage of these isolates [65]. The high rates of 
morbidity observed in many patients with enterococcal 
bloodstream infections, has led many to question 
whether enterococci can cause disease independently, 
other than in cases of SBE. There are studies which 
show that bloodstream infections caused by vancomycin- 
susceptible enterococci were associated with an 
attributable mortality, even when adjusted for under- 
lying disease 166,671. Does antimicrobial resistance in 
enterococci therefore lead to an adverse clinical 
outcome? In two studies marginal increases in mortality 
were found in cases caused by aminoglycoside-resistant 
enterococci 168,691. Noskin et al. 1651 also reported a 
higher infection-attributable mortality with E. faecium 
bacteremia than with E.faecalis bacteremia. The clinical 
effects attributable to glycopeptide resistance have 
varied in those studies that have compared clinical 
outcomes between VRE and VSE [70-761. The lack of 
co-morbidity data in some studies, such as the "IS, 
makes it difficult to estimate that portion of the 
mortality which is due to the enterococcal infection. 
The NNIS data 1771 collected between 1989 and 1993 
showed a significantly higher crude mortality for VRE 
when compared with VSE bacteremia (36.6% versus 
13.6%, p<O.OOOl).  Higher morbidity and mortality 
rates related to enterococcal bacteremia have been 
found in studies in which the patients had compro- 
mised host defences or serious illnesses-transplant 
patients, neutropenic patients and those in intensive 
care units [71-731. 
Risk factors for systemic infection by VRE include 
[64,70,78,79]: 
prolonged hospitalization especially in intensive care 
units 
severe underlying disease-immunocompromised 
status, neutropenia, organ transplantation, renal 
failure / dialysis 
prior nosocomial infection 
intra-hospital patient transfer 
prior colonization with VRE 
prior antibiotic usage, especially with third genera- 
tion cephalosporins and the carbapenems. 
During the last two decades there have been two 
major landmarks in acquired antibiotic resistance 
amongst the enterococci. First, high level amino- 
glycoside resistance and, secondly, high glycopeptide 
resistance. There have been several glycopeptide- 
resistance phenotypes described, of which Van A and 
Van B are the most common [18]. Antibiotic resistance 
has important implications for the management and 
outcome of cases of enterococcal bacteremia. N o  
optimal drug regimen for the treatment of VRE 
bacteremia has been found. Some VRE strains remain 
susceptible to ampicillin, which can therefore be used 
therapeutically. However, infections due to organisms, 
usually E.  faecium, with both high level penicillin and 
vanconiycin resistance, are much more of a challenge. 
Combination therapy with vancomycin plus genta- 
micin plus ampicillin have demonstrated efficacy in 
animal models, but their clinical effectiveness remains 
to be demonstrated [80]. Despite the fact that VRE of 
the Van B phenotype remain susceptible to teicoplanin 
in vitro, clinical efficacy with teicoplanin has not been 
universally successful, giving rise to the development of 
teicoplanin resistance [8 11. Other treatments include 
use of tetracyclines 1821 and the new agent quinu- 
pristin/dalfopristin, an antibiotic only effective against 
E.faecium. In one report a combination of minocycline 
and quinopristin/dalfopristin was synergistic, with a 
success rate of approximately 50% in neutropenic 
patients with VRE bacteremia [63]. 
There are major differences in the epidemiology of 
vancomycin-resistant enterococci (VRE) between the 
United States and Europe. In contrast with Europe, 
VRE in the United States are resistant to many 
antibiotics, and there appears to be less genetic vari- 
ability among these isolates. In comparison European 
VRE of human origin are usually susceptible to many 
other antibiotics and are highly polyclonal. These 
clinical isolates have the same susceptibility profiles as 
VRE isolated from animals. The differences in the 
spread of VRE between the United States and Europe 
might be explained by the over-consumption of 
glycopeptides and other antibiotics in American 
hospitals, and the use of avoparcin as a growth promoter 
in Europe [83]. 
Prevention is the best policy for the control of 
VRE and includes contact isolation, cohorting of 
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patients, isolation of colonized or infected patients and 
the appropriate use of glycopeptides and education of 
patients and staff. Strict handwashing is the most 
important and helpful recommendation [77]. 
STREPTOCOCCUS PNEUMONIA E 
Streptococcus pneumoniae is a common pathogen and a 
major cause of morbidity and mortality. In the United 
States alone it has been calculated that each year 
S. pneumoniae accounts for half a million cases of 
pneumonia, 55 000 cases of bacteremia and 6 000 cases 
of meningitis [84]. In some reports on bacteremia, 
S. pneumoniae is the second most common cause of 
community-acquired bacteremia in adults [85]. 
Increasing resistance to pencillin is now a worldwide 
phenomenon [86] with rates as high as 25-40% in 
Spain, leading to mortality rates of 20-54% [87,88]. In 
a report by Martinez et al. [89] among the 57 strains 
isolated from either blood or CSF, 18 (31.6%) and 8 
(14%), respectively, were intermediate or resistant to 
penicillin and 7 (12.3%) and 2 (3.5%), respectively, were 
intermediate or resistant to third-generation cephalo- 
sporins. 
Death caused by severe pneumococcal disease is 
related not only to the patient’s health, but also to 
features of the bacterium and antimicrobial therapy 
used [90]. In their study of 71 patients Gomez et al. 
[91] found the risk factors associated with penicillin- 
resistant pneumococcal bacteremia were: 
age >60 years 
severity of underlying disease 
previous lower respiratory tract infections 
previous use of p-lactam antibiotics 
Of the 71 patients, there was a 20% mortality and 
the factors associated with death were age, rapidly fatal 
underlying disease, nosocomial acquisition, initial 
clinical status, neutropenia and inappropriate antibiotic 
treatment. The degree of penicillin resistance did not 
significantly influence the clinical course or mortality. 
This study did not confirm the differences in risk 
factors found between penicillin-susceptible and 
penicillin-resistant pneumococcal bacteremia as found 
by Pallares et al. [88] in a retrospective series-previous 
hospital stay, nosocomial acquisition or pneumonia 
during the previous year. 
Does the degree of penicdhn resistance affect the 
clinical outcome of the patient? In the study of Pallares 
et al. [88] they found a significantly higher mortality in 
the penicillin-resistant group (54%) compared with the 
susceptible group (25%). However, Gomez et al. [91] 
found the influence of the degree of penicillin- 
resistance on the clinical course was not significantly 
different between the two groups. Other authors 
believe that the degree of antibiotic resistance does not 
significantly influence the risk of death, which mainly 
occurs as a result of the severity of the underlying 
disease, the initial status of the patient and the type of 
antibiotic treatment used [30,85,90-921. Inappropriate 
antibiotic treatment seems to be the main reason 
associated with a high mortality. In the treatment of the 
penicillin-resistant pneumococcal bacteremias, high 
doses of penicfin can achieve clinical and micro- 
biological cure [88,91,93]. 
Pradier et al. have found striking differences in 
penicillin susceptibility amongst various European 
countries [94]. In their study, data on penicillin- 
resistance patterns, antibiotic use and mode of adminis- 
tration and treatment compliance in five European 
countries (France, Spain, Germany, Italy and the UK) 
were compared. High prevalence rates of penicillin- 
resistant pneumococcal disease have been reported in 
Spain and France, where antibiotics are widely pre- 
scribed, and overall in Europe, patient compliance with 
more than 50% of oral antimicrobial prescriptions is 
inadequate. The low prevalence of penicillin resistance 
in Germany and the UK coincides with lower anti- 
biotic consumption and better treatment compliance 
in these countries. Recent attempts to raise public 
awareness and to restrict and improve indications for 
antimicrobial agents have resulted in decreased pneu- 
mococcal resistance in Hungary and Iceland, suggesting 
that pnuemococcal resistance can be reversed. 
Apart from p-lactam resistance, resistance to other 
antibiotics such as macrolides, tetracyclines and 
chloramphenicol have simultaneously increased [95]. 
Treatment of serious invasive penicillin-resistant 
pneumococcal disease, includmg bacteremia, remains 
third generation cephalosporin antibiotics such as 
cefotaxime and ceftriaxone [96]. 
The increasing resistance of S. pneumoniae to 
antimicrobial agents is a major cause for concern. 
Although several therapeutic strategies are possible, 
local patterns of resistance must be considered. It is 
essential to determine the susceptibility of individual 
strains to penicdlin and other antimicrobial agents that 
could be used for treatment. Communication between 
the clinician and the laboratory remains vital to 
determine the best therapeutic options. The recent 
recognition of cephalosporin-resistant strains empha- 
sizes the need to determine susceptibility to cephalo- 
sporins. Laboratories should be aware of the recently 
proposed changes in the definition of cephalosporin 
resistance, and clinicians need to be aware how these 
changes affect the choice of antibiotic therapy. Untd 
pneumococcal disease can be effectively prevented, by 
the use of better vaccines, we can expect resistant 
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pneumococcal infections to continue to pose thera- 
peutic difficulties. Even with optimum antibiotic 
therapy, the mortality from pneumococcal bacteremia, 
usually with underlying pneumonia, has remained at 
about 25% [88]. The emergence of antibiotic resistance 
in S. pneumoniae, with its associated problems of 
treatment, has encouraged immunization against 
pneumococcal infection. The pneumococcal23-valent 
polysaccharide vaccine is safe, but its protective efficacy 
is not certain; some studies and a meta-analysis of 
randomized controlled trials have shown rates of 
protection against pneumococcal bacteremia of 56- 
70% in the elderly [97]. 
VlRlDANS STREPTOCOCCI 
Streptococci of the viridans group have long been 
considered to be minor pathogens, except in subacute 
bacterial endocarditis. In the pre-antibiotic era, viridans 
streptococci accounted for 75% of cases of infective 
endocarditis [98]; in the current era their frequency has 
declined to 30%-40% [99]. For some years these 
bacteria have been the cause of serious bacteremia in 
neutropenic patients receiving intensive chemotherapy 
[ 1001. These infections can lead to severe complications 
such as endocarditis, respiratory distress syndrome, even 
shock [ lo l l ,  with association mortality rate of between 
10% and 30%. Principal risk factors [101,102] for these 
infections are: 
profound neutropenia 
antibiotic prophylaxis and co-trimoxazole or quino- 
lones 
use of H2 receptor antagonists 
oropharyngeal mucositis. 
Prevention of viridans streptococcal bacteremia 
in high-risk patients relies mostly on measures that 
minimize oral inflammation and decrease bacterial 
overgrowth. Use of prophylactic penicillin or vanco- 
mycin has been suggested, but is of questionable value 
and raises the spectre of selection of resistant strains 
[103]. Pfaller et al. [lo] found in the SCOPE National 
Surveillance Program that, in addition to penicillin- 
resistant strains of viridans streptococci from bac- 
teremias, there was also resistance to cefiriaxone (31%), 
erythromycin (51%) and 15% of strains were also 
resistant to ceftriaxone and erythromycin. 
STREPTOCOCCUS PYOGENES 
During the past decade there has been an increase in 
the prevalence of reported cases of group A strepto- 
coccal bacteremia. Many of the patients have been 
previously healthy adults between the ages of 20 and 50 
years. There has been an apparent increase associated 
with intravenous drug abusers [104,105] and noso- 
comial outbreaks in homes for the elderly [106,107]. 
Diabetes mellitus and peripheral vascular disease are 
important risk factors for the elderly where skin is the 
predominant portal of entry. Mortality ranges from 30 
to 40% [108,109]. 
Despite 50 years of extensive and often indis- 
criminate use of penicillin (‘sold over the counter’ in 
many countries) for the treatment of infections due to 
Streptococcus pyogenes, the organism continues to remain 
exquisitely susceptible to this antibiotic. Indeed no 
clinical isolate resistant to penicillin has been identified, 
and a recently completed survey of the susceptibility to 
penicillin of S. pyogenes strains isolated over a period of 
80 years has revealed no change in the activity of 
penicillin [110]. However, resistance to other anti- 
biotics does occur and reports of significant numbers 
of erythromycin-resistant S. pyogenes have appeared 
especially from Japan [ l l l ] ,  Finland [27,28] and Italy 
[112], usually associated with excessive macrolide con- 
sumption. 
CORYNEBACTERIUM JElKElUM 
Corynebacterium jeikeium is clinically regarded as the 
most important of the lipophilic Corynebacterium spp. 
These isolates were previously designated as C D C  
coryneform group JK bacteria [113], isolated from the 
skin of healthy people, mainly perineum and axilla. 
C. jeikeium can also be found as environmental contam- 
inants in hospitals [114]. C. jeikeium has been found 
to be the causative microorganism in endocarditis, 
bacteremia, meningitis, osteomyelitis and other noso- 
comial infections. The risk factors for acquiring or 
developing serious disseminated infections include 
immunosuppression, prosthetic devices (especially 
long-term central venous catheters, such as Hickman 
or Broviac), prolonged stay in hospital and prior 
exposure to broad spectrum antibiotics. Subacute 
endocarditis caused by C. jeikeium is more commonly 
associated with prosthetic than with normal heart 
valves [115]. Most clinical strains are resistant to p- 
lactam agents, macrolides, lincosamides and amino- 
glycosides; some strains are susceptible, in vitro, to the 
glycopeptides, fluoroquinolones and tetracyclines 
[116]. 
DISCUSSION 
The evolving dominant role of Gram-positive patho- 
gens is related to the high proportion of neutropenic 
and otherwise immunocompromised patients in our 
hospitals; the widespread use of intravascular devices 
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together with urinary, peritoneal and ventricular 
indwelling devices in the management of a variety of 
diseases and the expanded use of drugs with activity 
directed against Gram-negative organisms [16]. The 
range of effective compounds that are available for 
prophylaxis and treatment of infections due to Gram- 
negative organisms is significantly greater that those 
available for the management of Gram-positive 
infections. This results in a selective advantage to several 
Gram-positive species in the initial establishment of 
colonization prior to infection. For instance, acquisition 
of ampicillin-resistant strains of enterococci have been 
associated with exposure to multiple antibiotics [117]. 
Increasing incidence of infection with Gram-positive 
species is also associated with increasing antimicrobial 
resistance in this group of organisms, and alarming 
reduction in the range of therapeutic agents for such an 
infection. 
Infection control measures are a crucial element in 
preserving the effectiveness of currently available 
antimicrobial agents. Handwashing, improved hygiene 
and patient isolation have been identified as successful 
infection control measures. Purchasers and commis- 
sioning agencies for hospital services should put 
infection control and basic hygiene where they belong, 
at the heart of good hospital management and practice, 
and redirect resources accordingly. Such a policy will 
pay for itself quite quickly. Reduction in the blood- 
stream infection rates by multi-resistant Gram-positive 
bacteria, especially coagulase-negative staphylococci, is 
dependent upon strict adherence to published guide- 
lines for insertion and maintenance of intravascular 
catheters, use of intravasculars only when necessary and 
advances in the design and constituents of intravascular 
catheters [39,42,118-1201. 
Determination of current resistance patterns and 
the most appropriate empirical antibacterial treatment 
is best achieved by bacterial surveillance [121]. This can 
be done in individual hospitals, nationally between 
hospitals and internationally between countries. 
Microbiological surveillance provides vital information 
on the pathogens isolated from patients, particular 
hospital environments, and other sources, together with 
common patterns of antibacterial susceptibility. Sur- 
veillance is likely to be of greatest benefit in environ- 
ments such as intensive care units or transplant units 
including oncology, where patients are at  particular risk 
of acquiring nosocomial infections. Other benefits 
include the early detection of antibacterial resistance in 
specific bacteria and a reduction in the inappropriate 
use of antimicrobial agents. Studies have shown that 
infection control measures, together with microbio- 
logical surveillance, can significantly reduce infection 
rates and hospital costs. However, currently the 
collection of bacterial susceptibility data is incomplete 
and comprehensive national and international data 
are not yet established or the information is not 
made widely available. The microbiology laboratory 
influences antimicrobial drug usage through its routine 
reports and through consultations between microbio- 
logists and clinicians, but perhaps most importantly by 
providing continuing data collection and analysis [12]. 
This generally serves to reinforce exisiting hospital 
antibiotic policies, but can also identify emergrng 
problems to be addressed as part of the continuing 
dialogue between microbiologists and clinicians. Such 
dialogue is essential if we are to avoid losing valuable 
antimicrobial agents to acquired bacterial resistance. 
Development of a new antimicrobial agent costs 
c. A350 million, takes 7-10 years, and yields a product 
used for brief periods against targets prone to develop 
resistance, i.e. bacteria. The use of the new antibiotic 
may be restricted to delay resistance or to reduce costs. 
It is therefore easy to understand why pharmaceutical 
companies may prefer to invest their monies elsewhere, 
and the number of investigational new drug permits for 
antimicrobial agents issued by the FDA in the USA has 
fallen from 59 in 1993 to 12-22 in 1994-96. 
Many antibacterial agents have been launched in 
the past decade, but all are derivatives of old classes, and 
since resistance to the old class is (often) widespread, 
there is also the potential for rapid development of 
resistance in the new agents. In the past 15 years no 
new class of antimicrobial agents has been licensed. 
However, several new compounds presently under 
development have activity against multi-resistant Gram- 
positive organisms such as MRSA and VRE (Table 3). 
The oxazolidonones and everninomycins are the first 
new classes of antimicrobial agents to be developed 
for almost two decades. However it should be stressed 
that the compounds listed in Table 3 are at the 
developmental stage and there is no guarantee that they 
will be marketed. In addition, judging from past history, 
there are no reasons to believe that antibiotic resistance 
will not occur with these new compounds [122]. 
The author thanks Dr T. G. Winstanley for supply- 
ing Microbe Base data. 
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